Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
If you are researching NK cell therapy in Japan from abroad, you will probably see a phrase such as ‘provided under Japan’s regenerative medicine law.’ For many international patients, that phrase raises more questions than it answers. What does the law actually cover? Does it mean a treatment is approved? And what should you ask a clinic before booking a consultation? This article explains the framework in plain language so that you can approach your first conversation with a doctor with better questions.
Grand Green Osaka Umekita Clinic in Osaka (Umeda) provides NK cell therapy as a cancer immune cell therapy using a patient’s own cells. The information below is general background, not medical advice, and it cannot replace an individual assessment by a physician.
The short answer: oversight is not the same as approval
In Japan, treatments that use cultured or processed human cells fall under a dedicated system for regenerative medicine. Under this system, a clinic that wishes to offer a cell-based treatment must prepare a written plan describing the treatment, the facility that processes the cells, and the safety measures in place. The plan is reviewed by a committee and submitted to the national authorities before the treatment can be offered.
It is important to understand what this does and does not mean. The framework is designed to manage safety and transparency: who is allowed to process cells, how treatment is explained, and how problems are reported. It is not the same as a national finding that a therapy has been proven effective for a specific cancer. This is why NK cell therapy is described as a self-pay (non-insured) treatment, and why a careful, individual discussion with a doctor matters.
What the framework typically covers
Although the details vary by treatment, patients can generally expect the system to involve several elements. Understanding them helps you read a clinic’s explanation more critically.
- A treatment plan prepared in advance, describing how the cells are collected, processed, and returned.
- Review of that plan by a specialist committee before it is submitted to the authorities.
- Use of a licensed or notified cell processing facility for activating and expanding the cells.
- Written explanation to the patient and informed consent before treatment begins.
- Reporting of adverse events and periodic reporting on how the treatment is being provided.
These elements describe how a therapy is organized and monitored. They do not predict how any individual will respond, and they do not remove the need to discuss risks and limits directly with your doctor.
How this relates to NK cell therapy specifically
NK (natural killer) cells are a type of innate immune cell that can recognize and attack abnormal cells, including some cancer cells and virus-infected cells. In NK cell therapy, NK cells are obtained from a standard blood draw, activated and expanded at a specialized facility, and then returned to the patient by intravenous infusion. Because the cells come from the patient, the therapy is called autologous.
Since the cells are cultured outside the body, the regenerative medicine framework is the relevant legal pathway in Japan. The therapy is intended to be considered alongside, not instead of, standard cancer treatment such as surgery, chemotherapy, or radiation. Published research on NK cell approaches is still developing, and results from laboratory and early clinical studies should not be read as proof that the treatment works for every person or every type of cancer. A responsible clinic will say so plainly.
Questions to ask about oversight before you decide
You do not need legal expertise to ask good questions. The following points can help you judge whether a clinic is open about how it operates.
- Is this specific treatment covered by a plan that has been reviewed by a committee and submitted to the Japanese authorities, and can I see the relevant information?
- Where are my cells processed, and who is responsible for quality control?
- What side effects have been reported, and how are they managed if they occur? Temporary fever or fatigue has been described, but your own risk depends on your health.
- Which fees apply to each stage, and what happens to the cost if treatment is stopped or postponed?
- How will the clinic coordinate with the doctor treating my cancer in my home country?
- What are the realistic limits of this therapy for someone in my situation?
If answers are vague, or if a clinic promises a result, treat that as a reason to slow down. No treatment can guarantee an outcome, and the regenerative medicine framework does not change that.
Practical points for international patients
Medical travel adds practical questions. Treatment under this framework is self-pay, so fees are not covered by Japan’s national health insurance, and overseas insurance may not reimburse them either. It is sensible to confirm in writing what is included and to ask whether medical records, such as pathology reports and imaging, should be prepared in advance so that the doctor can review them during the consultation.
Language also matters, because informed consent only works if you fully understand what you are agreeing to. Grand Green Osaka Umekita Clinic offers an information page for international patients, and you can use it to learn how consultations are arranged. Whether you use that page or contact the clinic directly, you can request an explanation in a language you are comfortable with, and you can bring a family member or an interpreter to the discussion.
Putting it together before your consultation
Japan’s regenerative medicine framework gives patients a structure for asking about safety, facilities, and transparency. It does not decide, on its own, whether NK cell therapy is suitable for you. That decision depends on your diagnosis, your current treatment, your overall health, and your own priorities, and it belongs in a conversation with a physician who has reviewed your records.
Before you travel, write down your questions, gather your medical records, and ask for the fees, risks, and expected schedule to be explained to you in writing. NK cell therapy is a self-pay treatment, and its costs, risks, side effects, and eligibility should always be confirmed at a medical consultation. If you are considering a visit to Osaka, you can begin by contacting Grand Green Osaka Umekita Clinic to ask what information to prepare.
- Oversight, not approvalThe law sets a safety framework
- Ask about the planFacility, fees, and risks
- Self-pay treatmentConfirm costs in writing
- Doctor consultationSuitability is decided individually
This figure is a conceptual summary of the article content
References
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.